Counselling, HIV testing and adjunctive cotrimoxazole for TB patients in Malawi: from research to routine implementation.
METHODS
Fifteen hospitals in Malawi that offer voluntary counselling and testing (VCT) for the human immunodeficiency virus (HIV) for tuberculosis (TB) patients and cotrimoxazole (CTX) for patients found to be HIV-positive.


OBJECTIVE
1) To describe the process of developing a national TB-HIV plan, conducting a country-wide situational assessment, and producing national guidelines on VCT and CTX for TB patients, and 2) to assess the implementation of VCT and CTX for TB patients registered between July and September 2003.


METHODS
A descriptive study.


RESULTS
The 3-year HIV-TB plan was finalised in 2002. Between January and March 2003, an assessment was carried out of HIV/AIDS and joint HIV-TB services in Malawi and a decision made to support 15 hospitals in implementing VCT and CTX for TB patients. Between April and June 2003, national guidelines on VCT and CTX were developed through a consultative process, and treatment units were prepared for implementation. Between July and September 2003, 2397 TB patients were registered, and 1404 (59%) accepted VCT; 956 (68%) were HIV-positive, of whom 927 (97%) started CTX. Deficiencies in the registration process and in patient understanding about VCT and CTX were identified.


CONCLUSIONS
The results show that it is feasible to routinely implement VCT and CTX for TB patients.
Community Health Science Unit, National Tuberculosis Control Programme, Lilongwe, Malawi.
R B
RB
Chimzizi
A D
AD
Harries
E
E
Manda
A
A
Khonyongwa
F M
FM
Salaniponi
D015492:AIDS Serodiagnosis; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use*; D003376:Counseling; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000150:complications / Q000453:epidemiology; D006801:Humans; D008295:Malawi / Q000453:epidemiology; D009313:National Health Programs / Q000458:organization & administration*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use*; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy* / Q000453:epidemiology; D035141:Voluntary Programs
D000890:Anti-Infective Agents; D000995:Antitubercular Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination